D. E. Shaw & Co., Inc. Intercept Pharmaceuticals, Inc. Put Options Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $1 Million - $1.33 Million	-75,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$12.99 - $20.47 $714,450 - $1.13 Million	55,000 Added 275.0%	75,000 $1.11 Million
Q2 2020 Aug 14, 2020	BUY	$46.7 - $92.04 $467,000 - $920,400	10,000 Added 100.0%	20,000 $958,000
Q4 2019 Feb 14, 2020	SELL	$57.36 - $124.1 $229,440 - $496,400	-4,000 Reduced 28.57%	10,000 $1.24 Million
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $352,140 - $482,759	-6,000 Reduced 30.0%	14,000 $929,000
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $274,528 - $404,672	-3,200 Reduced 13.79%	20,000 $2.02 Million
Q3 2018 Nov 14, 2018	BUY	$88.49 - $127.55 $725,618 - $1.05 Million	8,200 Added 54.67%	23,200 $2.93 Million
Q1 2018 May 15, 2018	SELL	$52.72 - $67.25 $543,016 - $692,675	-10,300 Reduced 40.71%	15,000 $923,000
Q4 2017 Feb 14, 2018	SELL	$58.2 - $72.76 $1.78 Million - $2.22 Million	-30,500 Reduced 54.66%	25,300 $1.48 Million
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $3.18 Million - $6.63 Million	55,800	55,800 $3.24 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.